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Abstract
The HER4 intracellular domain (4ICD) is a potent estrogen receptor (ERα) coactivator with activities in breast cancer and 
the developing mammary gland that appear to overlap with progesterone receptor (PgR). In fact, 4ICD has recently 
emerged as an important regulator and predictor of tamoxifen response, a role previously thought to be fulfilled by 
PgR. Here we investigated the possibility that the 4ICD coactivator regulates PgR expression thereby providing a 
mechanistic explanation for their partially overlapping activities in breast cancer. We show that 4ICD is both sufficient 
and necessary to potentiate estrogen stimulation of gene expression. Suppression of HER4/4ICD expression in the 
MCF-7 breast tumor cell line completely eliminated estrogen stimulated expression of PgR. In addition, the HER4/4ICD 
negative MCF-7 variant, TamR, failed to express PgR in response to estrogen. Reintroduction of wild-type HER4 but not 
the γ-secretase processing mutant HER4V673I into the TamR cell line restored PgR expression indicating that 4ICD is an 
essential PgR coactivator in breast tumor cells. These results were substantiated in vivo using two different 
physiologically relevant experimental systems. In the mouse mammary gland estrogen regulates expression of PgR-A 
whereas expression of PgR-B is estrogen independent. Consistent with a role for 4ICD in estrogen regulated PgR 
expression in vivo, PgR-A, but not PgR-B, expression was abolished in HER4-null mouse mammary glands during 
pregnancy. Coexpression of PgR and 4ICD is also commonly observed in ERα positive breast carcinomas. Using 
quantitative AQUA IHC technology we found that 4ICD potentiated PgR expression in primary breast tumors and the 
highest levels of PgR expression required coexpression of ERα and the 4ICD coactivator. In summary, our results 
provide compelling evidence that 4ICD is a physiologically important ERα coactivator and 4ICD cooperates with ERα to 
potentiate PgR expression in the normal and malignant breast. We propose that direct coupling of these signaling 
pathways may have important implications for mammary development, breast carcinogenesis, and patient response 
to endocrine therapy.
Findings
Breast cancer is the most frequently diagnosed cancer in
North American women and the second leading cause of
cancer related death. The natural history, as well as the
clinical outcome, of breast cancer are dependent upon
the interplay between multiple growth promoting path-
ways with the estrogen receptor α (ERα) among the most
important. In fact, ERα is expressed in up to 75% of pri-
mary breast tumors [1] and therapeutic management of
patients with ERα positive tumors will involve an endo-
crine component with tamoxifen being the most com-
monly prescribed. The high percentage of breast tumors
with  de novo or acquired resistance to tamoxifen has
prompted clinicians and researchers to investigate addi-
tional predictive markers for endocrine therapy response.
One reasonable tumor marker is the estrogen regulated
progesterone receptor (PgR). The prevailing paradigm
suggests that lack of PgR tumor expression indicates dis-
engaged ERα signaling and therefore concomitant loss of
the ERα tumor growth signal and therapeutic target.
However, preclinical studies demonstrate that ERα sig-
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naling remains intact in tamoxifen resistant cells despite
the loss of PgR expression [2].
In a recent study, loss of tumor expression of the recep-
tor tyrosine kinase HER4/ERBB4 (referred to here as
HER4) was an independent marker for tamoxifen resis-
tance [3]. HER4 has emerged as a unique cell-surface
receptor and several novel HER4 signaling activities in
breast cancer are in fact mediated by an independently
signaling HER4 intracellular domain (4ICD). For exam-
ple, 4ICD is a potent ERα coactivator selectively regulat-
ing gene expression and breast tumor cell proliferation in
response to estrogen [4,5]. In addition, our group has
recently demonstrated that tamoxifen disruption of the
4ICD/ERα transcriptional complex results in breast
tumor cell killing, in part, by driving mitochondrial accu-
mulation of 4ICD [6]. Within the mitochondria, 4ICD
functions as a proapoptotic BH3-only protein [4,6-8].
Accordingly, cytosolic 4ICD is associated with tumor cell
apoptosis and improved patient prognosis [9]. The role of
4ICD as an ERα coactivator and the apparent overlapping
ability of 4ICD and PgR to predict patient outcome to
tamoxifen raises the possibility that 4ICD regulates estro-
gen stimulated PgR expression in the breast. However,
the ERα coactivator function of 4ICD remains to be vali-
dated in vivo.
W e  a n d  o t h e r s  h a v e  s h o w n  t h a t  H E R 4  p o t e n t i a t e s
estrogen stimulated expression of an ERE-luciferase
reporter [5,10]. We further demonstrated that inactiva-
tion of the γ-secretase processing site within HER4
(HER4V673I) prevents generation of 4ICD and abolished
HER4/4ICD coactivator activity [8]. We next wanted to
determine if independently expressed 4ICD was suffi-
cient to coactivate ERα and enhance estrogen stimulated
gene expression. HER4 potentiated estrogen stimulated
expression of an ERE-luciferase reporter by over 10 fold
whereas the γ-secretase processing mutant, HER4V673I,
failed to impact estrogen stimulated gene expression (Fig-
ure 1A) [5]. Western blot analysis of transfected cell
lysates indicated equivalent levels of HER4 and
HER4V673I expression (Figure 1B). Similar to HER4,
independently expressed 4ICD enhanced estrogen stimu-
lated gene expression by over 10-fold (Figure 1A). Taken
together these results indicate that 4ICD is both neces-
sary and sufficient to coactivate estrogen stimulated gene
expression.
We next determined the impact of HER4 expression on
estrogen stimulated expression of endogenous PgR in the
ERα-positive MCF-7 breast tumor cell line. RNAi medi-
ated knockdown of endogenous HER4 completely abol-
ished the ability of estrogen to stimulate expression of
PgR in MCF-7 cells (Figure 2A). We substantiated these
results in the MCF-7 variant TamR which lacks endoge-
nous HER4 expression [6]. Estrogen stimulation of wild-
type MCF-7 cells significantly upregulated PgR expres-
sion, however, estrogen failed to stimulate significant lev-
e l s  o f  P g R  e x p r e s s i o n  i n  t h e  T a m R  c e l l s  ( F i g u r e  2 B ) .
Reintroduction of HER4, but not the γ-secretase process-
ing mutant HER4V673I, restored estrogen regulation of
PgR expression (Figure 2B). Therefore, the ability of
HER4 to restore endogenous PgR expression requires γ-
secretase processing to generate the 4ICD coactivator.
Low expression levels of another 4ICD coregulated gene,
stromal cell-derived factor 1 (SDF-1) [5], was observed in
the TamR and HER4V673I cell lines, but similar to PgR
optimal SDF-1 expression required reintroduction of
HER4 (Figure 2C).
We next examined the developing mouse mammary
gland to confirm 4ICD coactivation of PgR expression in
vivo. There is significant phenotypic overlap between
HER4, ERα, and PgR deficient mammary glands. Specifi-
cally, each receptor appears to be essential for pregnancy-
induced lobuloalveolar development [11-17]. Further-
more, we have observed dramatic nuclear localization of
the 4ICD coactivator within mammary epithelium coin-
cident with the essential role of HER4 during pregnancy
[4,13]. To determine if 4ICD coactivates PgR expression
in vivo we examined expression of the PgR isoforms PgR-
A and PgR-B in HER4-null mammary glands by western
blot (Figure 3A). Significantly, at 14.5 days post-coitus
(P14.5) PgR-A expression was suppressed in the HER4
deficient mammary glands whereas PgR-B expression
Figure 1 The HER4 intracellular domain (4ICD) is necessary and 
sufficient to potentiate estrogen stimulated gene expression. (A) 
MCF-7/B (MCF-7 cells with ectopic BCL-2 expression) [22] breast can-
cer cells were incubated in growth media supplemented with 5% 
charcoal-stripped FBS (CS-FBS) for 24 hrs and cotransfected with 200 
ng of ERE-luc and the indicated HER4 (JM-a, Cyt1 isoform) or 4ICD ex-
pression vectors. At 24 hrs post-transfection cells were cultured in the 
presence or absence of 100 pM 17-β-estradiol (Estrogen) and the lu-
ciferase reporter gene assay was performed after 16 hrs as described 
previously [5]. Each sample was prepared in duplicate and the entire 
experiment was repeated at least three times. Data represents the 
mean and standard error of luciferase activity normalized to untreated 
cells transfected with ERE-Luc alone. (B) Protein lysates prepared from 
the same experimental treatments were analyzed by western blot for 
HER4/4ICD (Cell Signaling 111B2) expression with β-tubulin (Upstate 
DM1A) included as a loading control.Rokicki et al. Molecular Cancer 2010, 9:150
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appeared to be unaffected (Figure 3B). This result was
confirmed by immunohistochemistry (IHC) where PgR-
A expression was significantly suppressed in HER4 defi-
cient mammary glands at P14.5 (Figure 3C and 3D).
Interestingly, PgR-A, but not PgR-B, is estrogen regulated
and coexpressed with ERα in the mammary gland [18].
These observations and our results strongly implicate the
4ICD/ERα transcriptional complex as an important regu-
lator of in vivo PgR-A expression in the mammary gland.
In breast cancer PgR expression represents a clinically
important indicator of prognosis. In light of recent evi-
dence indicating that the 4ICD coactivator is an impor-
tant effector of tumor response to tamoxifen [6] and
possibly fulvestrant [19], 4ICD coregulation of PgR
expression in breast tumors could have important clinical
implications. We used a sophisticated automated quanti-
tative analysis (AQUA) algorithm [20,21] to measure lev-
els of ER, PgR, and nuclear or cytoplasmic 4ICD in
primary human breast tumors by IHC (Figure 4A-D).
AQUA analysis allows detection of continuous and subtle
differences in tumor protein levels by IHC. To determine
if 4ICD coactivates PgR expression in breast carcinomas
we quantitated the levels of PgR expression in 196 ther-
apy naive PgR positive breast tumors using the AQUA
IHC procedure [20,21].
Consistent with other clinical studies, chi-square analy-
sis of patient groups selected by ERα expression demon-
strated a lack of PgR expression in the absence of ERα
(Figure 4E) (p < 0.0001). Although ERα expression alone
was sufficient to promote PgR expression in breast
tumors, the levels of PgR expression were significantly
potentiated in tumors coexpressing ERα with nuclear
4ICD (PgR AQUA 21.7 vs. 30.0; p = 0.025) indicating that
Figure 2 4ICD is required for estrogen stimulated expression of 
PgR. (A) Suppression of endogenous HER4 expression was performed 
in MCF-7 cells using erbB-4/Her4 siRNA SMARTpool or Nonspecific siR-
NA Negative Control Pool and siIMPORTER transfection reagent (Up-
state Biotechnology, Lake Placid, NY) as described elsewhere [5]. 
Transfected cells were cultured in growth media supplemented with 
5% CS-FBS for 48 hrs and incubated in the presence or absence of 100 
pM 17-β-estradiol (Estrogen) for an additional 16 hrs. Total RNA was ex-
tracted and PgR expression was analyzed by RT-PCR. β-actin RNA was 
amplified as a control for RNA quantitation. (B) The MCF-7 variant TamR 
[23] lacking endogenous HER4 expression [6] was stably transfected 
with an EGFP vector, HER4-EGFP, or the γ-secretase processing mutant 
HER4V673I-EGFP which fails to generate 4ICD. Each cell line was incu-
bated in growth media supplemented with 5% CS-FBS for 48 hrs and 
incubated in the presence or absence of 100 pM 17-β-estradiol (Estro-
gen) for 2 or 16 hrs. Total RNA was extracted and (B) PgR or (C) SDF-1 
expression was analyzed by RT-PCR. β-actin RNA was amplified as a 
control for RNA quantitation. All RT-PCR reactions and conditions in-
cluding primer sequences have been described elsewhere [5]. Results 
indicate that the 4ICD coactivator is essential for estrogen stimulated 
PgR and SDF-1 expression in the MCF-7 variant.
Figure 3 HER4 regulates PgR expression in the mouse mammary 
gland. (A) Transgenic mice expressing HER4 under the control of the 
cardiac specific myosin promoter were crossed with HER4+/- mice 
(both kindly provided by Jon Golding, Open University) to generate 
HER4-/-;HER4heart (HER4-/-) mice [17]. Mammary glands were collected 
and snap frozen in liquid nitrogen or spread on a glass slide, fixed over-
night in formalin, processed, and paraffin embedded. Lysates were 
prepared from P14.5 mammary glands and analyzed by western blot 
using an antibody that recognizes (A) HER4 (Cell Signaling 111B2) or (B) 
both PgR-A and PgR-B isoforms (DAKO A0098). (C) Immunofluorescent 
localization of PgR-A in mammary glands at P14.5. After antigen re-
trieval by pressure cooker treatment in citrate buffer, sections were in-
cubated in peroxidase block followed by DAKO block before overnight 
incubation with the PgR-A specific anti-PgR sc-538 (Santa Cruz) [18] 
antibody. Secondary antibody was Alexa 555-conjugated (Invitrogen) 
and nuclei were counterstained with DAPI. Arrowheads indicate nucle-
ar staining of PgR-A. (D) The number of PgR-A-positive alveolar cells 
were quantitated from images captured using a TCS SP2 Leica confo-
cal microscope with an Acousto-Optical Beam Splitter. Mammary 
glands from three mice per genotype were analyzed and a minimum 
of 1000 alveolar cells per mouse were counted. Results are expressed 
as mean +/-SEM. Statistical significance was determined using the Stu-
dent's t test. A significant (p = 0.0112) 2.95-fold reduction in PgR-A pos-
itive alveolar cells was observed in mammary glands lacking HER4 
expression when compared to wild-type control mammary glands.Rokicki et al. Molecular Cancer 2010, 9:150
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the 4ICD coactivator potentiates PgR expression in breast
tumors. This association was significantly strengthened
at the highest levels of PgR expression. In fact, PgR
AQUA levels > 50 were significantly associated with ERα
and nuclear 4ICD coexpression (p < 0.04) but not ERα
expression alone (p > 0.09) (Figure 4E). These observa-
tions demonstrate that the 4ICD coactivator potentiates
ERα regulated PgR expression during breast tumorigene-
sis and robust tumor expression of PgR requires ERα
coexpression with the 4ICD coactivator. These results
further implicate 4ICD as an important ERα coactivator
regulating estrogen stimulated gene expression in pri-
mary breast tumors.
Conclusions
In summary, we provide compelling evidence from multi-
ple  in vitro and  in vivo experimental systems that the
4ICD transcriptional coactivator cooperates with ERα to
regulate PgR expression in the normal and malignant
breast. The potential clinical impact of these findings is
underscored by the recent emergence of 4ICD as a criti-
cal effector of tamoxifen action [6] as well as an impor-
tant tumor marker predicting patient response to
tamoxifen [3,6]. Our results suggest that PgR expression
represents a clinical surrogate marker for tumor expres-
sion of 4ICD, a potent ERα coactivator and regulator of
tamoxifen action.
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